Alere Financial Says Bio-Reference Laboratories' Reimbursement Volatility has Created an Opportunity

In a report published Friday, Alere Financial analyst Raymond Myers reiterated a Buy rating and $36.00 price target on

. In the report, Alere Financial noted, “On November 27, BRLI preannounced disappointing guidance for F4Q and reduced projected F2014 growth of 10%. After speaking with Management and assessing an important subsequent CMS decision to reconsider proposed pathology reimbursement cuts, we are maintaining our BUY rating and $36.00 Price Target. In our experience, BRLI has been a volatile stock and investors tend to outperform when buying on weakness.” Bio-Reference Laboratories closed on Wednesday at $29.55.